Cancer Section, Developmental Biology & Cancer Programme, Institute of Child Health, University College London, London, UK.
Cancer Research UK & UCL Cancer Trials Centre, Cancer Institute, University College London, 90 Tottenham Court Road, London W1T 4TJ, UK.
Eur J Cancer. 2015 Jan;51(2):225-32. doi: 10.1016/j.ejca.2014.10.026. Epub 2014 Nov 22.
The UKW3 trial compared biopsy/pre-operative chemotherapy versus immediate nephrectomy and afforded the opportunity to examine the influence of percutaneous retroperitoneal biopsy and other factors on local and distant relapse of Wilms tumour (WT).
Patients with unilateral WT (stages I-IV) excluding metachronous relapse or early progressive disease were eligible. Metastatic and 'inoperable' tumours were biopsied electively. 'Local' was defined as relapse within the abdomen, except for liver metastases considered as 'distant' relapse, together with other haematogenous routes. Uni- and multivariable analyses estimated the risk factors for relapse.
Overall, 285/635 (44.9%) patients had a biopsy. With a median follow-up of 10.1 years, 35 (5.5%) patients experienced a 'local', 15 a combined (2.4%) and 60 (9.4%) a 'distant' relapse. On univariate analysis, biopsy, anaplasia and tumour size were associated with an increased risk of local relapse. On multivariable analysis, anaplasia and tumour size remained significant for local relapse whereas the elevated risk of biopsy (hazards ratio (HR) = 1.80: 95% confidence interval (CI) 0.97-3.32, p = 0.060) was marginal. Age, anaplasia, tumour size, lymph nodes metastases and stage, but not biopsy, were individually associated with increased risk of distant relapse but only age and anaplasia remained significant following multivariable analysis.
The UKW3 trial provides some reassurance that biopsy should not automatically lead to 'upstaging' of WT. Further assessment of this controversial area is required. Comparison of local relapse rates in a multinational trial in which the United Kingdom (UK) continued the practice of routinely biopsying all patients in contrast to the standard European approach will afford this opportunity and is planned.
UKW3 试验比较了活检/术前化疗与即刻肾切除术,并提供了检查经皮腹膜后活检和其他因素对肾母细胞瘤(WT)局部和远处复发影响的机会。
单侧 WT(I-IV 期)且无同步复发或早期进行性疾病的患者符合条件。转移性和“不可切除”的肿瘤选择性进行活检。“局部”定义为腹部内复发,除肝转移视为“远处”复发外,还有其他血行转移途径。单变量和多变量分析评估了复发的危险因素。
总体而言,635 例患者中有 285 例(44.9%)进行了活检。中位随访 10.1 年后,35 例(5.5%)患者发生“局部”复发,15 例(2.4%)为联合(2.4%)复发,60 例(9.4%)为“远处”复发。单变量分析显示,活检、间变和肿瘤大小与局部复发风险增加相关。多变量分析显示,间变和肿瘤大小仍然与局部复发显著相关,而活检的风险升高(风险比(HR)=1.80:95%置信区间(CI)0.97-3.32,p=0.060)具有边缘意义。年龄、间变、肿瘤大小、淋巴结转移和分期,但不是活检,与远处复发风险增加相关,但多变量分析后仅年龄和间变仍然显著。
UKW3 试验提供了一些保证,即活检不应自动导致 WT 的“升级”。需要进一步评估这一有争议的领域。在一项多国试验中比较局部复发率,该试验中英国(UK)继续常规对所有患者进行活检,而欧洲标准方法则不进行活检,这将提供这种机会,并计划进行比较。